The PD-1 proteins transmembrane ligands, expressed by T-lymphocytes, inhibit the immune response when they join with their PD-L1 and PD-L2 ligands, expressed predominately by tumor cells, diminishing the defense mechanisms of the immune system due to the loss of cytotoxic activity of T lymphocytes. Here, PDCD1LG2 is linked to neoplasm.